Date: 2017-05-30
Type of information: Licensing agreement
Compound: isatuximab (SAR650984), SAR566658, SAR408701, additional antibody drug conjugate directed to an undisclosed target, SAR428926
Company: Immunogen (USA - MA) Sanofi (France)
Therapeutic area: Cancer - Oncology
Type agreement: licensing - development - manufacturing - commercialisation
Action mechanism: monoclonal antibody/antibody drug conjugate (ADC)
Disease:
Details:
- • On May 30, 2017, ImmunoGen announced that the company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen's technology.
- Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the following experimental compounds in development: isatuximab (SAR650984), an unconjugated anti-CD38 antibody in Phase 3 development for relapsed and refractory multiple myeloma; SAR566658, an ADC targeting CA6 in Phase 2 development for triple negative breast cancer (TNBC); SAR408701, an anti-CEACAM5 ADC being studied for the treatment of solid tumors; and an additional ADC directed to an undisclosed target.
- ImmunoGen and Sanofi have also amended a separate 2013 exclusive license to grant Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the experimental compound SAR428926, an anti-LAMP1 ADC being studied for the treatment of solid tumors.
Financial terms: As consideration for these amendments, ImmunoGen will receive a $30 million payment and has agreed to forego a limited co-promotion option in the U.S. with respect to the compounds covered by the 2003 agreement, as well as future milestones or royalties under both license agreements.
Latest news:
Is general: Yes
